Regeneron (NASDAQ:REGN) reported positive Phase 2 data for its thrombosis drug candidates REGN7508 and REGN9933 and plans to ...

The efficacy and safety of apixaban for VTE prophylaxis in major orthopedic surgery have been evaluated in one Phase II trial and three Phase III trials. Traditional treatment of acute VTE entails ...

For people taking popular blood thinners after having a blood clot, a reduced dose may limit the future risk of bleeding as ...

The research team focused the study on the two most prescribed direct oral anticoagulants, or DOACs, rivaroxaban (brand name ...

For people taking blood thinners after experiencing a blood clot, a new study suggests that reducing the dose after six ...

Anticoagulation with apixaban or rivaroxaban may be used to reduce thromboembolism risk, but be wary of fracture risk.

A recent case published in the journal ACG CASE REPORTS JOURNAL found a possible risk of colonic ischemia caused by the usage ...

Purpose The pharmacology, pharmacokinetics, efficacy, and safety of apixaban are reviewed. Summary Apixaban is an oral, direct, selective factor Xa inhibitor with a rapid onset of action.